Pulmonary interstitial glycogenosis: Diagnostic evaluation and clinical course

  • Deborah R. Liptzin
  • , Christopher D. Baker
  • , Jeffrey R. Darst
  • , Jason P. Weinman
  • , Megan K. Dishop
  • , Csaba Galambos
  • , John T. Brinton
  • , Robin R. Deterding

Research output: Contribution to journalReview articlepeer-review

34 Scopus citations

Abstract

Objectives: We sought to describe the phenotype for patients with P.I.G. including presentation, evaluation, cardiac co-morbidities, high resolution computed tomography findings, and outcomes. Methods: With institutional review board approval, we performed a retrospective review of patients with biopsy-proven P.I.G. Biopsies, high resolution chest computed tomography, and cardiac evaluations were reviewed and characterized by experts in each field. Results: Sixty-two percent of the patients were male. The median gestational age was 37 weeks (range 27-40). The median age at biopsy was 1.6 months (range 0.3-6 months). Structural heart disease was present in 63% of patients. Pulmonary hypertension (diagnosed by echocardiogram and/or cardiac catheterization) was noted in 38% of patients. Alveolar simplification was present in 79% of patients. Fifty percent of available biopsies revealed patchy disease. An increase in age at biopsy was associated with patchy (vs diffuse) disease. Ninety-two percent of patients were treated with systemic corticosteroids. Median age at last follow-up was 1234 days with a range of 37 days to 15 years. At the time of last follow-up, 12 patients were off all support, eight were on supplemental oxygen, two were mechanically ventilated, one underwent lung transplantation, and one died. CT findings commonly included ground glass opacities (86%) and cystic change (50%). Conclusions: The P.I.G. phenotype has not been comprehensively described, and poor recognition and misconceptions about P.I.G. persist. P.I.G. is a disease that presents in early infancy, requires significant medical intervention, and frequently is seen in association with alveolar simplification and/or cardiovascular disease. CT findings include ground glass opacities and cysts. Patients should be monitored for pulmonary hypertension. Without life-threatening comorbidities, many patients do well over time, although respiratory symptoms may persist into adolescence.

Original languageEnglish
Pages (from-to)1651-1658
Number of pages8
JournalPediatric Pulmonology
Volume53
Issue number12
DOIs
StatePublished - Dec 2018

Funding

The authors wish to thank Deborah Batson for her assistance with i2b2. Robin Deterding is Co-Founder, Board member, and consultant Triple Endoscopy, Inc., Co-Founder and Board member Now Vitals, Inc., and Pediatric Interstitial Lung Disease Consultant, Boehringer Ingelheim.

FundersFunder number
K23HL121090
Boehringer Ingelheim GmbH

    Keywords

    • biopsy
    • cysts
    • glucocorticords
    • infant newborn
    • interstitial lung diseases
    • oxygen
    • phenotype
    • pulmonary hypertension

    Fingerprint

    Dive into the research topics of 'Pulmonary interstitial glycogenosis: Diagnostic evaluation and clinical course'. Together they form a unique fingerprint.

    Cite this